Evaluation of the Immunological Efficiency for Some of COVID-19 Vaccines (Pfizer, AstraZeneca and Sinopharm) among Vaccinated People of Wasit Province in Iraq

Abstract

Background: Coronaviruses (SARS-CoV-2) cause Severe Acute Respiratory Syndrome COVID-19 pandemic in March, 2020. After Chinese scientists published the genome of the virus vaccine manufacturer produced several COVID-19 vaccines that aimed to induce a humoral and cellular immune response to prevent the fatality and harm caused by COVID-19. Existing study aimed to evaluate the immunological activity of some approved vaccines in terms of serological tests for antibodies (IgG and IgM) for the study groups in Wasit Governorate.Methods: The current study sample included (55) individuals who were vaccinated with two doses of one of the three vaccines and did not suffer from chronic health problems, (35) unvaccinated individuals of both genders. Their age ranges from 18-45 years, they were divided into two age ranges (18-31 and 32-45 years) and their vaccination history was confirmed according to a special form. The blood samples were collected from vaccinated individuals 2-4 weeks after the second dose of COVID-19 vaccine for the purpose of conducting immunological assays for immunoglobulins (IgG, IgM) and C- reactive protein (CRP) using ELISA kits.Results: The results of serological immunoassay tests for (IgM) for the vaccinated participants, both age groups and both genders with the three Pfizer, AstraZeneca and Sinopharm vaccines were documented a positive percentage of (47 %), (64 %) and (42 %) and negative (53 %), (36%) and (58%) respectively. Whereas, the (IgG) among vaccinators with the same three vaccines was recorded a positive percentage (100%) and negative (0%) in terms of a significant rise (P≤0.05) in serum antibody levels (IgG) in all the three vaccines (Pfizer, AstraZeneca and Sinopharm) in both age ranges and for both genders compared to the control group (unvaccinated individuals).Conclusions: the findings of the present study, that all three vaccines (Pfizer, AstraZeneca and Sinopharm) have shown a high efficacy and safely against coronavirus disease (COVID-19) in terms of the immune responses of the vaccinators. Current study data indicated a non-significant difference among age ranges (18-31 and 32-45 year) and gender is not associated with IgG levels.